Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jul;168(3):415-423.
doi: 10.1007/s11060-024-04681-8. Epub 2024 Apr 22.

Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study

Yutaro Koide  1 , Naoya Nagai  2   3 , Sou Adachi  4 , Masayuki Ito  5 , Mariko Kawamura  3 , Makoto Ito  4 , Fumitaka Ito  5 , Yurika Shindo  2 , Takahiro Aoyama  2 , Hidetoshi Shimizu  2 , Shingo Hashimoto  2 , Hiroyuki Tachibana  2 , Takeshi Kodaira  2
Affiliations
Multicenter Study

Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study

Yutaro Koide et al. J Neurooncol. 2024 Jul.

Abstract

Aim: We aimed to investigate the impact of concurrent antibody-drug conjugates (ADC) and radiotherapy on symptomatic radiation necrosis (SRN) in breast cancer patients with brain metastases (BM).

Methods: This multicenter retrospective study uses four institutional data. Eligibility criteria were histologically proven breast cancer, diagnosed BM with gadolinium-enhanced MRI, a Karnofsky performance status of 60 or higher, and radiotherapy for all BM lesions between 2017 and 2022. Patients with leptomeningeal dissemination were excluded. Concurrent ADC was defined as using ADC within four weeks before or after radiotherapy. The cumulative incidence of SRN until December 2023 with death as a competing event was compared between the groups with and without concurrent ADC. Multivariable analysis was performed using the Fine-Gray model.

Results: Among the 168 patients enrolled, 48 (29%) received ADC, and 19 (11%) had concurrent ADC. Of all, 36% were HER2-positive, 62% had symptomatic BM, and 33% had previous BM radiation histories. In a median follow-up of 31 months, 18 SRNs (11%) were registered (11 in grade 2 and 7 in grade 3). The groups with and without concurrent ADC had 5 SRNs in 19 patients and 13 SRNs in 149, and the two-year cumulative incidence of SRN was 27% vs. 7% (P = 0.014). Concurrent ADC was associated with a higher risk of SRN on multivariable analysis (subdistribution hazard ratio, 3.0 [95% confidence interval: 1.1-8.3], P = 0.030).

Conclusions: This study suggests that concurrent ADC and radiotherapy are associated with a higher risk of SRN in HER2-positive breast cancer patients.

Keywords: Antibody–drug conjugates; Brain metastases; Radiation necrosis; Radiotherapy; Trastuzumab deruxtecan; Trastuzumab emtansine.

PubMed Disclaimer

References

    1. Barbour AB, Jacobs CD, Williamson H et al (2020) Radiation Therapy Practice Patterns for Brain Metastases in the United States in the Stereotactic Radiosurgery Era. Adv Radiat Oncol 5:43–52. https://doi.org/10.1016/j.adro.2019.07.012 - DOI - PubMed
    1. Gondi V, Bauman G, Bradfield L et al (2022) Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 12:265–282. https://doi.org/10.1016/j.prro.2022.02.003 - DOI - PubMed
    1. Ladbury C, Pennock M, Yilmaz T et al (2024) Stereotactic Radiosurgery in the Management of Brain Metastases: A Case-Based Radiosurgery Society Practice Guideline. Adv Radiat Oncol 9:101402. https://doi.org/10.1016/j.adro.2023.101402 - DOI - PubMed
    1. Murthy RK, Loi S, Okines A et al (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 382:597–609. https://doi.org/10.1056/NEJMoa1914609 - DOI - PubMed
    1. Lin NU, Borges V, Anders C et al (2020) Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol 38:2610–2619. https://doi.org/10.1200/JCO.20.00775 - DOI - PubMed - PMC

Publication types

Substances

LinkOut - more resources